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Background: T regulatory (Treg) cells are important in balancing immune responses and dysregulation of Treg cells
has been implicated in the pathogenesis of multiple disease states including asthma. In this study, our primary aim
was to determine Treg cell frequency in the peripheral blood of children with and without asthma. The secondary
aim was to explore the association between Treg cell frequency with allergen sensitization, disease severity and
medication use.
Methods: Peripheral blood mononuclear cells from healthy control subjects (N = 93) and asthmatic children of
varying disease severity (N = 66) were characterized by multi-parameter flow cytometry.
Results: Our findings demonstrate that children with asthma had a significantly increased frequency of Treg cells
compared to children without asthma. Using a multivariate model, increased Treg cell frequency in children with
asthma was most directly associated with inhaled corticosteroid use, and not asthma severity, allergic sensitization,
or atopic status of the asthma.
Conclusion: We conclude that low dose, local airway administration of corticosteroids is sufficient to impact the
frequency of Treg cells in the peripheral blood. These data highlight the importance of considering medication
exposure when studying Treg cells and suggest inhaled corticosteroid use in asthmatics may improve disease
control through increased Treg cell frequency.
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The CD25+ T regulatory (Treg) cell, a widely accepted T
cell subset with immune suppressive properties, was ini-
tially thought to exist primarily to prevent autoimmune
diseases [1]. Increasing evidence suggests that Treg cells
are important in varied immune responses, including
allergic diseases [2-6]. A role for Treg cells in allergic
disease was first highlighted in Immunodysregulation,
Polyendocrinopathy, Enteropathy, X-linked (IPEX)
patients [7,8]. IPEX patients lack Treg cells and have
increased serum IgE levels, skewing of T cell responses* Correspondence: cmseroogy@wisc.edu
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reproduction in any medium, provided the ortoward a Th2 phenotype, and autoimmune endocrinopa-
thies [9]. In allergic disease, the current concept suggests
that inadequate Treg cell suppression of effector cells or
diminished Treg cell numbers contributes to the develop-
ment and perpetuation of allergic inflammation [10,11].
Studies utilizing murine models of allergic asthma provide
strong evidence for an essential Treg cell role in modulat-
ing allergic airway inflammation [12-16]. Two recent
clinical studies have suggested that Treg cells in adult
asthmatic subjects are elevated while another study
demonstrated diminished Treg cells in asthmatic children
[17-19]. Therefore, the role of Treg cells in allergic asthma
remains poorly defined, particularly in children when the
initiation of allergic asthma most often occurs.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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responses and inflammation, we hypothesized that children
with asthma would have fewer Treg cells compared to un-
affected children. One of the challenges of identifying Treg
cells is the lack of a unique marker. Published studies ana-
lyzing human Treg cells have utilized several phenotypic
markers including CD25, CD127, and Foxp3. In this study,
we used multi-parameter flow cytometry to investigate the
frequency of Treg cells in the peripheral blood of children
ages 7–8 years with or without asthma. The frequency of
Treg cells was further analyzed in relationship to disease
severity, allergic sensitization and medication use.
Methods
Study subjects and design
Analysis of peripheral blood mononuclear cells (PBMC)
from 159 children ages 7–8 years was performed using flow
cytometry. Subjects were enrolled in the Childhood Origins
of ASThma (COAST [20]) study at birth (N = 141) or were
newly recruited based on a diagnosis of asthma (N = 18).
COAST is a high-risk birth cohort in that at least 1 parent
was required to have a history of physician-diagnosed
asthma and/or documented allergen sensitization (defined
as one or more positive aeroallergen skin prick tests)
[20,21]. Flow cytometry was performed in children en-
rolled in COAST over a one-year period. Children within
the cohort were classified as having asthma as defined
below. Additional children with a physician diagnosis of
asthma were recruited to enrich the sample for children
with asthma, and were age-matched to those enrolled in
the COAST birth cohort. An effort was made to enroll
equal numbers of children with intermittent, mild persist-
ent and moderate/severe persistent asthma. This study
was approved by University of Wisconsin Human Subjects
Committee and legal guardians of all subjects provided
informed consent.
Asthma definition and severity
Asthma was diagnosed as previously described by study
physicians using National Asthma Education and Preven-
tion Program (NAEPP) Expert Panel Report Guidelines
[21,22]. Medication use was assessed by questionnaire at
the study visit. Since asthmatic children were taking medi-
cation at enrollment, asthma classification was based on
medication use and symptom control. Classification was as
follows: 1) children well-controlled without a daily control-
ler medication were classified as intermittent; 2) children
well-controlled on low dose ICS or leukotriene receptor
antagonist were classified as mild persistent; 3) children
requiring medium dose ICS or two classes of controller
medication for asthma (ICS + long acting beta agonist,
medium dose ICS or medium-high dose ICS + leukotriene
receptor antagonist) were classified as moderate persistent;
and 4) children requiring high dose ICS plus long-actingbeta agonist were classified as severe persistent (medication
use in each subject as it relates to asthma severity is listed
in Additional file 1). Spirometry was performed using the
Jaeger MasterScreen system at the study visit. Eigen cri-
teria for lung function were used, similar to those used in
published studies [23,24]. If the child was ill, requiring
albuterol or with asthma symptoms, the visit was resched-
uled. Respiratory viral surveillance nasal samples were
collected on all subjects for another study. Virology data
from a subset of the study patients (N = 49) was analyzed
for respiratory viral infections and symptoms were scored
as previously described [22]. Respiratory viral panel ana-
lysis from 49 subjects demonstrated no viral detection in
43 subjects and 6 subjects were virus positive (2 human
rhinovirus, 2 coronavirus, 1 RSV, and 1 influenza). Add-
itionally, symptom scores from 134 of the 159 study sub-
jects were obtained. The majority of subjects (N = 110,
82%) denied recent respiratory infection symptoms at the
time of blood draw for flow cytometry. 10 of those 134
were symptomatic: 7 mild (symptom score 1–4) and 3
moderate (symptom score 5–6). All 10 had respiratory viral
panel analysis. Viral detection rates were 67% (2/3) for
moderate illness, 29% (2/7) for mild illness, and 5% (2/39)
for asymptomatic visits.Flow cytometry
PBMCs were isolated using Ficoll density gradient, incu-
bated with Fc block (eBiosciences, San Diego, CA) and
then stained in media with the following antibodies: CD3-
Pacific Blue (clone UCHT1, eBiosciences), CD4-PerCP
(clone RPA-T4), CD25-APC (clone 2A3), CD127-PE (clone
hIL-7R-M21) (BD Biosciences, San Jose, CA) and FoxP3-
Alexa Fluor 488, (clone 206D, BioLegend, San Diego, CA,
USA) according to manufacturer’s protocol within 24 hours
of blood draw. Cells were acquired on a LSR II (BD Bios-
ciences). Positive staining and gating strategy was deter-
mined by comparison to isotype or Fluorescence Minus
One (FMO) control. Data were analyzed using Flowjo
software (Treestar, San Carlos, CA).Total IgE and allergy tests
Total and allergen-specific IgE for birch, grass mix, rag-
weed, Dermatophagoides pteronyssinus, Dermatophagoides
farinae, Alternaria alternata, cat, dog, cockroach, egg, and
peanut were analysed by UniCAP 100 fluoroenzyme im-
munoassay (FEIA, Pharmacia and Upjohn Diagnostics,
Kalamazoo, MI). The sensitivity for detection of total IgE
was 2 kU/L. Allergen-specific IgE values of ≥ 0.35 kU/L
were considered positive. Birch, grass mix, ragweed
were considered seasonal allergens and dust mite, cat,
dog, alternaria, and cockroach were considered peren-
nial allergens.
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Demographic characteristics were compared by asthma
diagnosis using chi-square tests for association. The fre-
quency of Treg cells was compared using one-factor
(asthma, asthma with ICS, asthma severity, atopic asthma,
FEIA) and two-factor (asthma severity & ICS, atopic
asthma & ICS, FEIA & ICS) ANOVA models. Results of
two-factor ANOVA models are summarized using least
squares means (estimated marginal means for a balanced
population). The Treg cell percentage is displayed in the
figures as mean ± 95% confidence interval (CI) or standard
deviation (SD). The association between Treg cell percent-
age and total IgE (log-transformed) was analyzed using
Pearson’s correlation coefficient. A two-sided p-value < 0.05
was regarded as significant.Results
Study population
Table 1 outlines the characteristics of the study subjects.
The percentage of children with asthma was 42% with noTable 1 Characteristics of study subjects
Disease classification No asthma Intermittent
Number of subjects 93 31
Age(years) (±SD) 7.6 ± 0.8 7.6 ± 0.5
Female 46 (49%) 10 (32%)
Male 47 (51%) 21 (68%)
Caucasian 89 (96%) 29 (94%)
African American 3 (3%) 3 (10%)
American Indian 4 (4%) 0 (0%)
Asian 0 (0%) 1 (3%)
Hispanic or Latino 4 (4 %) 1 (3%)
Spirometry(median [25th, 75th])
FEV1 1.50 [1.37, 1.72] 1.54 [1.27, 1.66]
FEV1% pred 103 [95, 109] 103 [89, 113]
FVC 1.85 [1.64, 2.06] 1.81 [1.60, 2.05]
FVC% pred 108 [100, 115] 110 [98, 118]
FEV0.5 1.11 [1.01, 1.30] 1.14 [0.97, 1.29]
FEF25-75 1.63 [1.23, 1.95] 1.54 [1.03, 1.88]
PEF 2.98 [2.58, 3.50] 3.20 [2.59, 3.65]
FEV1/FVC 0.85 [0.79, 0.88] 0.82 [0.77, 0.86]
FEV0.5/FVC 0.63 [0.58, 0.69] 0.60 [0.55, 0.65]
Total lgE (median [25th, 75th]) 38 [19, 92] 49 [15, 103]
Any FEIA 40/91 (44%) 16/29 (55%)
Aero FEIA 38/91 (42%) 16/29 (55%)
Perennial aero FEIA 34/91 (37%) 15/29 (52%)
Seasonal aero FEIA 23/91 (25%) 7/29 (24%)
FEV1 Forced Expiratory Volume at 1 second, FEV1%pred FEV1 percent predicted, FVC
Expiratory Volume at 0.5 second, FEF25-75, Forced expiratory flow at 25% to 75% of FVCsignificant difference in gender. The children with asthma
were more likely to be African American. There were
trends for inverse associations between FEV 0.5, PEF and
FVC and asthma disease severity. Asthma diagnosis and
disease severity were significantly associated with perennial
allergen sensitization and total IgE, but not seasonal aller-
gen sensitization (Table 1). Additionally, body mass index
(BMI) was recorded for 66% of the subjects at the time of
blood draw for Treg cell analysis. Within this subset, there
is no difference in BMI by asthma status or ICS use (data
not shown).Peripheral blood Treg cell frequency is increased in
children with asthma
We first sought to define the optimal approach for determin-
ing Treg cell frequency in a pediatric population. We analyzed
PBMC by multi-parameter flow cytometry using a combin-
ation of phenotypic markers for Treg cells. In our cohort,
similar to published work in adults [25], the CD4+CD25+
CD127lo/- T cells expressed the majority of Foxp3 proteinMild persistent Moderate/severe persistent p value
15 20
7.4 ± 0.8 7.4 ± 1.0 0.54
6 (40%) 8 (40%) 0.38
9 (60%) 12 (60%)
11 (73%) 16 (80) 0.008
6 (40%) 6 (30%) <0.0001
0 (0%) 0 (0%) 0.84
0 (0%) 0 (0%) 0.42
1 (7%) 0 (0%) 0.83
1.23 [1.09, 1.63] 1.46 [1.29, 1.83] 0.11
90 [85, 101] 102 [94, 107] 0.43
1.62 [1.31, 1.93] 1.88 [1.51, 2.21] 0.06
96 [94, 116] 114 [105, 120] 0.19
0.92 [0.78, 1.18] 1.07 [0.97, 1.21] 0.07
1.21 [0.98, 1.51] 1.48 [1.25, 1.70] 0.16
2.46 [2.16, 2.99] 2.66 [2.51, 3.17] 0.07
0.82 [0.81, 0.88] 0.81 [0.77, 0.86] 0.43
0.62 [0.56, 0.65] 0.57 [0.55, 0.65] 0.24
149 [20, 331] 218 [103, 475] 0.001
11/15 (73%) 17/20 (85%) 0.003
11/15 (73%) 17/20 (85%) 0.002
11/15 (73%) 16/20 (80%) 0.001
4/15 (27%) 9/20 (45%) 0.33
forced vital capacity, FVC%pred, FVC percent predicted; FEV0.5, Forced
; PEF, peak expiratory flow rate; Aero FEIA, aeroallergen fluoroenzyme immunoassay.
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CD25+CD127+ T cells (Figure 1B); however Foxp3 expres-
sion per cell was lower than in CD4+CD25+CD127lo/- T
cells (Figure 1C). This finding is consistent with low level
Foxp3 being an activation marker in effector T cells [26-31].
Based on these findings, we used the combination of CD25,
CD127, and Foxp3 to define Treg cells.
Analysis of PBMC revealed a significantly increased per-
centage of CD4+CD25+CD127lo/- T cells in children with
asthma compared to non-asthmatics (Figure 2). Interestingly,
the Treg cell frequency was significantly higher in boys com-
pared to girls (girls: 6.1 [5.7-6.5, 95%CI] vs. boys: 7.0 [6.7-7.3];
p = 0.001, data not shown). After adjustment for gender,
increased Treg cell frequency remained significantly asso-
ciated with a diagnosis of asthma. There was no significant
difference in the percentage of Foxp3 positive cells within the
CD4+CD25+CD127lo/- T cells or the mean fluorescent in-
tensity (MFI) of Foxp3 between the groups (data not shown).Increased peripheral blood Treg cell frequency is
associated with inhaled corticosteroid use and not
asthma disease severity
We considered several possibilities for the observed
increased frequency of Treg cells including a compensatory
mechanism for airway inflammation or a secondary medi-
cation effect. Subjects were therefore categorized based on
asthma disease severity and medication use. When asth-
matic children were stratified based on inhaled corticoster-
oid (ICS) use, the increased frequency of Treg cells was
positively related to intermittent or daily ICS use (Figure 3).
When ICS use and asthma disease severity were considered
in a 2-factor model, ICS use but not asthma severity was
associated with increased Treg cell frequency (Table 2). ICS
use remains significantly associated with increased Treg cell
frequency after adjustment for gender (p = 0.001). StudyFigure 1 CD4 + CD25 + CD127lo/- T cells express the majority of high
cytometry as described in the methods section. Lymphocytes were gated u
gating. A. Within this defined gate, CD127 and CD25 staining was determin
subject is shown out of 159 assayed with the percentage of each populatio
isotype control. The percentage of Foxp3 staining within each defined qua
CD3 + CD4 + CD25 + CD127lo/-: 71.1%; SD 14.7%). The CD127 + CD25+ T ce
within the CD3 + CD4 + CD25 + CD127+: 20.8%; SD 11.1%). C. Mean Fluores
the highest amount of Foxp3 per cell. The mean MFI for Foxp3 in CD3 + C
CD127+ T cells: 146 SD 49.4.subjects with documented respiratory viral infections
tended to have higher Treg cells, though this was not sig-
nificant (+0.7, 95% CI −0.5 to +1.9, p = 0.28) and ICS use is
still significantly associated with higher Treg cell frequency
after adjusting for infection.Peripheral blood Treg cell frequency is increased in
children with allergen sensitization
Allergic sensitization is a major risk factor associated with
the childhood asthma [32], but studies investigating the as-
sociation between Treg cells and allergic sensitization have
been conflicting [33-35]. To better understand the relation-
ships among Treg cells, allergic sensitization and asthma,
we examined the association between total IgE levels,
allergen-specific sensitization, and Treg cell frequency. We
found a positive correlation between serum total IgE levels
and peripheral blood Treg cell frequency (R = 0.24,
p = 0.003, data not shown). In addition, there was a trend
for increased Treg cells in sensitized children (FEIA nega-
tive: 6.37% [5.99, 6.75] vs. FEIA positive: 6.82% [6.48, 7.17],
p = 0.09, data not shown). When these two factors were
considered in the same model, ICS use but not allergic
sensitization was associated with an increased frequency of
Treg cells (Table 3).
Lastly, we asked whether relationships between ICS and
asthma depended on atopic status. When non-atopic
asthmatics were separated from atopic asthmatics, the
increased frequency in Treg cells was associated with ICS
use, regardless of atopic status (Table 4). Subjects with
asthma were more likely to have rhinitis (74% vs. 42%), data
not shown, and asthma with ICS use had higher rates of
rhinitis compared to asthma without ICS (83% vs. 62%).
However, when adjusting the analysis for rhinitis, we still
find that Treg cell frequency is significantly higher with ICS
use (p = 0.005).level Foxp3 protein. PBMCs were isolated and stained for flow
sing forward and side scatter profiles followed by CD3 and CD4
ed using fluorescence minus one (FMO) controls. One representative
n in upper right corner. B. Foxp3 staining was determined using an
drant is plotted for the entire cohort (mean% of Foxp3+ cells within
lls have a subset of low expressing Foxp3+ cells (mean% of Foxp3+
cent Intensity (MFI) for Foxp3 is shown. CD25 + CD127lo/- cells display
D4 + CD25 + CD127lo/- T cells: 377 SD 137.8 vs. CD3 + CD4 + CD25 +
Figure 2 Peripheral blood Treg cells are increased in children
with asthma. The percentage CD3 + CD4 + CD25 + CD127lo/- T cells
in the peripheral blood of asthmatics (6.91% [6.52, 7.3]) versus control
(6.4% [6.07, 6.73]) children. Data are expressed as the mean percentage
of Treg cells within gated CD3 + CD4+ T cells with 95% CI.
Table 2 Increased Treg cell frequency is associated with
ICS use and not asthma disease Severity
Patient
Classification












40 7.37 1.06 (0.15,
1.96)
No asthma 93 6.93 – – 0.96
Intermittent 31 6.77 -0.17 (-0.91,
0.57)




20 6.91 -0.02 (-1.17,
1.12)
Interaction: P = 0.78
ICS Inhaled corticosteroid, 95% CI, 95% confidence interval.
*differences in least squares (LS) means in%Treg cells/CD4+ cells between
the groups.
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In this study, we characterized the frequency of Treg cells
in the peripheral blood of 159 children. To the best of our
knowledge, this is the largest number of allergic asthmatic
children analyzed using multi-parameter flow cytometryFigure 3 Peripheral blood Treg cells are increased in asthmatic
children using inhaled corticosteroids independent of asthma
severity. The percentage of Treg cells in the peripheral blood is
elevated in asthmatics treated intermittently (Int) or daily with ICS.
Data are expressed as the percentage of Treg cells within gated
CD3 + CD4+ T cells with 95% CI. No asthma: 6.4% (6.08, 6.73);
Asthma no ICS: 6.24% (5.64, 6.84); Asthma Int ICS: 7.42% (6.54, 8.31);
Asthma daily ICS: 7.34% (6.74, 7.94).for Treg cell frequency determination. Our findings
demonstrated a statistically significant association between
increased frequency of Treg cells and intermittent or
chronic ICS use. This association was independent of
asthma disease severity, allergic sensitization, gender, BMI,
or other atopic disease status. These findings indicate that
ICS use is associated with an elevation in Treg cell fre-
quency and that intermittent ICS use is sufficient for this
systemic change to occur. This increase in Treg cell fre-
quency observed with ICS use represents 1% of the total
CD4+ cells and approximately 17% of the Treg cells.
Moreover, these data suggest that inhaled corticosteroids
may work by shifting the balance of adaptive immune
responses toward Treg cell predominance. Lastly, our
findings suggest that ICS treatment is an important
covariate to consider in studies of Treg cells in asthma.Table 3 Increased Treg cell frequency is associated with
ICS use and not allergic sensitization
Patient
Classification












39 7.32 0.94 (0.32,
1.55)
FEIA negative 71 6.76 – – 0.51
FEIA positive 84 6.94 0.18 (-0.35,
0.71)
Interaction: P = 0.93
ICS, inhaled corticosteroid; FEIA, fluroenzyme immunoassay; 95% CI, 95%
confidence interval.
*difference in LS means in%Treg cells/CD4+ cells between the groups. Four
children missing FEIA data were excluded from the analysis.
Table 4 Increased Treg Cell Frequency is Associated with
ICS Use and Not Asthma Status
Patient
Classification












39 7.55 1.26 (0.40,
2.12)
No asthma 93 7.03 – – 0.68
Non-atopic
asthma
20 7.05 0.02 (-0.80,
0.84)
Atopic asthma 44 6.69 -0.34 (-1.18,
0.50)
Interaction: P = 0.35
ICS Inhaled corticosteroid, 95% CI, 95% confidence interval.
*difference in LS means%Treg cells/CD4+ cells between the groups. Two
asthma subjects are missing FEIA data and were excluded from the analysis.
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used to define Treg cells. Recent work from our group
utilizing multi-parameter flow cytometry alongside the
demethylation status of a region of the Foxp3 promoter
(Treg specific demethylated region,TSDR) found the
strongest positive relationship using CD4 + CD25 +
CD127lo/- T cells as the Treg cell defining phenotype
when compared to CD4 + CD25 + CD127lo/-Foxp3+ T
cells [36]. This finding suggests Foxp3 protein levels
may not be constantly detectable using flow cytometry
in bona fide Treg cells. Thus, multi-parameter flow cyto-
metry using CD25 and CD127 to define Treg cells is re-
liable for quantification of CD4+ T cells expressing high
levels of Foxp3 protein and demethylation at TSDR.
The impact of corticosteroids on Treg cells in asthma
has not been extensively studied. It has been reported that
corticosteroid exposure leads to increased Foxp3 mRNA
expression in peripheral blood CD4+ T cells from adult
asthmatics treated with oral and inhaled corticosteroids
[37]. Smyth et al. demonstrated an increased frequency of
CD4 + Foxp3+ T cells in the bronchial alveolar lavage fluid
(BALF) in adult patients with moderate-to-severe asthma
compared to mild asthmatics and healthy controls, but
did not account for medication use or atopic status of the
patients [18]. In our study, all of the moderate-to-severe
asthmatics were on ICS, and a subset of the study subjects
(16%) had one or more bursts of oral corticosteroids
(OCS) during the study period. In contrast to ICS, the use
of OCS was not significantly associated with increased
Treg cell numbers (p = 0.80, data not shown). Our find-
ings in peripheral blood suggest that the increased fre-
quency of BALF Treg cells in the study by Smyth et al.
might also be secondary to ICS use. Hartl et al. studied
a small number of children with symptomatic asthma
(n = 18) demonstrating diminished BALF Treg cell, defined
as CD4 +CD25hi, frequency with normalization afterinitiation of ICS use compared to control groups [19].
Yuksek et al. noted an increase in peripheral blood Treg
cells, defined as CD4 + CD25hiFoxp3+, in a small number
of asthmatic children (n = 16) after initiation of inhaled
corticosteroids [38]. In general, our data are in agreement
with the observation that ICS use increases Treg cell
frequency, and indicate that there are similar changes
in the blood and airway. Our data further clarifies the rela-
tionship of ICS and Treg cells using a more rigorous def-
inition of Treg cells with multi-parameter flow cytometry,
an increased sample size, and presents a more thorough
characterization of other atopic characteristics (allergic
sensitization, asthma severity, atopic status).
Several mechanisms could contribute to a positive as-
sociation between ICS use and increased Treg cells. For
example, corticosteroids enhance Foxp3 transcription
[37,39]. Alternatively, ICS could alter homing character-
istics of Treg cells, or represent a compensatory re-
sponse to dampen ongoing lung inflammation. Similarly,
the positive association between serum IgE and Treg cell
frequency could represent a compensatory response to
allergic inflammation. Additional studies are warranted
to investigate longitudinal changes in Treg cells before
and after ICS use. These lines of investigation would
help support a mechanism of action for ICS and may
serve as a prognostic indicator of response to therapy.
Recently, several studies have implicated Treg cell dys-
function in allergic asthmatics [4,19]. Further analysis of
Treg cells in our cohort, including quantifying the per-
centage of Foxp3+ T cells within the defined Treg cell
population and MFI of Foxp3, did not reveal any signifi-
cant differences with these indirect measurements of
Treg cell function. This remained consistent when sub-
jects were segregated by asthma, disease severity, or ICS
use (data not shown). Studies further phenotyping the
Treg cell compartment and analyzing functional charac-
teristics are ongoing in our laboratory.
Conclusions
In summary, our study demonstrates an increased fre-
quency of Treg cells in the peripheral blood of asthmatic
children using ICS. This relationship suggests that cor-
ticosteroid use should be considered when analyzing the
frequency of Treg cells in asthma. The modest increase
(~17%) in Treg cell frequency was observed even with
intermittent ICS use. These findings suggest the possibility
that ICS-mediated increases in Treg cell frequency could
contribute to the beneficial ICS effects on asthma disease
control.
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